Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03831724
Other study ID # MDT18047
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date July 2019
Est. completion date May 2020

Study information

Verified date November 2019
Source Medtronic - MITG
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Multicenter, Prospective, Non-Randomized clinical trial to define and validate normative data of EGJ-distensibility measurements and contractile patterns in healthy subjects.

Asymptomatic subjects will be enrolled at up to 7 clinical sites in the United States.

Subjects who meet inclusion and no exclusion criteria and are deemed asymptomatic will be eligible for study enrollment.

The procedure visit/s will consist of the following procedures: High resolution manometry (HRM), esophagogastroduodenoscopy (EGD), endolumenal functional lumen imaging probe (EndoFLIP) and a Bravo procedure.

A post procedure follow-up phone call will be conducted within 5-9 days of completing all procedures.

HRM, EGD, and Bravo procedures are performed to evaluate subjects as normal in addition to being asymptomatic. Abnormal results in one or more of the procedures identifies the subject as unhealthy and the subject will be withdrawn from the study.

The expected duration of subject's participation in the study is up to 70 days (up to 30 days from screening to HRM, up to 30 days to complete EGD, EndoFLIP and Bravo, plus 5-9 days for follow up call).

Enrollment duration - up to 1 year


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date May 2020
Est. primary completion date February 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Healthy male or female ages 18-75 years.

2. The subject has the ability to give informed consent.

3. The subject has the ability to undergo sedation, as assessed and determined by the treating physician or the anesthesiologist.

4. BMI range of 18-30 kg/m2.

5. Asymptomatic subjects as assessed by gastro-esophageal reflux disease questionnaire (GERDQ) negative score of less than 8 points (GERDQ <8) and brief esophageal dysphagia questionnaire (BEDQ) negative score of 0 points (BEDQ score=0), as assessed and determined by treating physician.

Exclusion Criteria:

1. Subject has known or suspected major gastrointestinal motility disorders including but not limited to major esophageal motility disorders, EGJ outflow obstruction and delayed gastric emptying.

2. Subject has dysphagia or any swallowing disorder.

3. Subject has an inability to tolerate nasal intubation.

4. Subject has a known or suspected bleeding diathesis.

5. Subject with known or suspected Gastroesophageal Reflux Disease (GERD), or subject has symptoms of GERD.

6. The subject has a known or suspected esophageal disease or disorder such as eosinophilic esophagitis (EOE), Barretts esophagus, severe esophagitis, upper GI bleeding or esophageal varices.

7. Subject is known or is suspected to suffer from an esophageal stricture or obstruction.

8. Subject has a hiatal hernia.

9. Subject with medical comorbidities such as diabetes, hypertension hyper/hypothyroidism, or chronic obstructive pulmonary disease (COPD)

10. Subject with a diagnosed autoimmune disease.

11. Subject who has undergone prior upper GI surgery or interventions such as esophageal myotomy, fundoplication, dilatation or stent.

12. Subject has a history of any malignancy.

13. Subject has a history of any seizure disorder.

14. Subject has a history of an eating disorder/s.

15. Subject has an active history of nicotine use, cannabis use or alcohol abuse (as defined by: greater than 14 drinks/week or 4 drinks/day for men, 7 drinks/week or 3 drinks/day for women. A standard drink is defined as 12 oz of beer, 5 oz of wine, or 1.5 oz of liquor). Subject has used any tobacco, nicotine or cannabis products in the last 6 months or has abused alcohol in the last 6 months.

16. Subject taking or prescribed or over-the-counter any acid suppressant medications (for example proton-pump inhibitors), any medication that treats reflux or heartburn symptoms (for example Tums and Maalox), any anticoagulant medications, any opiate medication or medication with known impact on GI motility.

17. Subject has any allergy or other contraindication to the device components or to study medication used prior and/or during the procedure.

18. Subject has a known sensitivity or allergy to nickel or other heavy metals.

19. Subject has any condition, which according to the investigators judgment, precludes compliance with study and/or device instructions.

20. Females who are pregnant or nursing at the time of screening and/or during the study period or are sexually active and of child bearing potential without medically acceptable methods of contraception.

21. Subject who has a cardiac pacemaker or implantable cardiac defibrillator.

22. Subject who has a general contraindication for upper endoscopy.

23. Subject who is currently participating in another clinical study (investigational drug or device).

24. Subject who is considered to be part of a vulnerable population (e.g. prisoners or those without sufficient mental capacity).

25. Medtronic employees.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
EndoFLIP™ System with FLIP Topography Module
The EndoFLIP system with the EF-322N catheter will be used. The EndoFLIP system is a tool that assesses esophageal, esophago-gastric junction (EGJ)/lower esophageal sphincter (LES), and pylorus function. It allows the measurement of LES and pylorus distensibility as well as esophageal contractile activity in response to distension. The system uses impedance planimetry to measure luminal cross-sectional area (CSA) along an axial plane during volume-controlled distention.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Medtronic - MITG

Outcome

Type Measure Description Time frame Safety issue
Primary Define and validate normative data of esophago-gastric junction -distensibility index (EGJ-DI) measurements at 60mL in healthy subjects Median, 25% and 75% percentile for EGJ-DI measurements at 60mL balloon fill volume 70 days
Secondary To define and validate normative data for an EGJ-DI at different balloon fill volumes within the same subject Mean and median EGJ-DI at different balloon fill volumes of the same subject 70 days
Secondary To define and validate normative data for a maximum restrictive EGJ diameter at different balloon fill volumes within the same subject Mean and median maximum restrictive EGJ diameter at different balloon fill volumes of the same subject 70 days
Secondary To define and validate normative data of a distal esophageal body diameter at different balloon fill volumes within the same subject Mean and median distal esophageal body diameter at different balloon fill volumes of the same subject 70 days
Secondary To define and validate normative data of contractile patterns at different balloon fill volumes within the same subject Presence of Repetitive antegrade contractions (RACs) and number of antegrade contractions at different balloon fill volumes of the same subject
Presence of Repetitive Retrograde Contractions (RRCs) and number of retrograde contractions at different balloon fill volumes of the same subject
70 days
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1